Dishman Pharmaceuticals has abandoned plans to set up a special economic zone (SEZ) citing law changes that make the project less attractive and unfavourable economics as the reasons for the decision.
BASF has sold its chitosan biopolymers business to Norway-based Seagarden ASA continuing the divestiture of the non-core units it acquired as part of Cognis in 2010.
Scientists have uncovered a new simple way to “clean” genotoxic impurities (GTIs) in drug ingredients by mixing the solution with contamination-eating scavengers.
IPEC (International Pharmaceutical Excipients) Federation is calling on foreign gelatin makers to set up manufacturing plants in India in a bid to tackle an “acute” shortage of the excipient.
Contract manufacturing organisations (CMOs) have been busy in the past week, with OsoBio expanding its plant and AMRI adopting a new relationship strategy.
Fluctuating raw material prices mean market knowledge is a must for companies competing in the intermediates and ingredients space according to Granules India.
Royal DSM NV has confirmed that Percivia – its biosimilars joint venture (JV) with Crucell - is to cease in-house product development after failing to agree on future investment and says that job losses are likely.
The SFDA has closed down 10 gel capsule factories and revoked two licenses after finding 23 batches of products tainted with “excessive levels” of the toxic metal chromium.
Indian contract manufacturer Surya Pharmaceutical has received an EDQM Certificate of Suitability (CEP) for an antibiotic API and approval for its Banur plant from Teva.
The American Business Council (ABC) has warned US drugsmakers working in Pakistan to brace themselves for supply chain disruptions as the Government imposes heavy delays on the process used to allocate raw materials to manufacturers.
More post-acquisition integration in the pharma excipients space this week with Ashland launching a new product line combining its own techs with coatings it bought with International Specialty Products (ISP) in 2011.
RNA therapeutics developer Arrowhead Research has bought Alvos Therapeutics in the hope that peptide targeting technology will help it overcome delivery challenges.
Lonza and Agennix have made a tactical alliance over the Phase III production of a non-small cell lung cancer therapy in the hopes it will improve the chance of joint manufacturing after the commerical launch.
in-PharmaTechnologist brings you a round-up of the latest new facilities and expansions for drugsmakers, including added cytotoxic capabilities for BTL, Jubilant’s launch of a special economic zone in India and plans for a $20m API plant for Omkar.
